Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Illumina, Inc. - Common Stock (NQ: ILMN )

84.70 +0.65 (+0.77%)
Streaming Delayed Price Updated: 11:58 AM EDT, Mar 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Illumina, Inc. - Common Stock

< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
31 32 Next >
Illumina Announces Job Layoffs After CEO Resignation, Icahn's Board Chess Game: What's Next?
Biotechnology company Illumina, Inc. (NASDAQ: ILMN) initiated layoffs within its research and development (R&D) team, affecting approximately 10% of that staff. 
Via Benzinga
S&P 500: Carnival, Tesla Headline Big-Cap Losers Monday
Carnival rebounded from its 21-day, while Tesla is tumbling toward it. 
Via Investor's Business Daily
CEO Shuffle: 7 Stocks That Could Gain Momentum From New Leadership
New CEOs and other top managers can revitalize companies. For example, here are seven stocks to gain momentum from leadership changes. 
Via InvestorPlace
If You Invested $1000 In This Stock 20 Years Ago, You Would Have $140 Thousand Today
Via Benzinga
Medical Stocks Waters, Agilent, Illumina Show Growth Potential
Medical-sector stocks Waters, Agilent, and Illumina appear to be trading at low valuations relative to their future growth prospects, according to analysts. 
Via MarketBeat
Illumina's CEO Was Just Ousted: Should Investors Buy In Now or Steer Clear?
Things aren't looking up just yet. 
Via The Motley Fool
Illumina CEO Steps Down; Grail Soap Opera Continues
And we interview Anjay Nagpal, host of the podcast "Brokers, Bagmen, and Moles." 
Via The Motley Fool
Ominous Death Cross Forms On Illumina's Chart
Via Benzinga
How to Retire Rich: Biotech Stocks Edition
Thanks to its enormous and practically permanent relevancies, the biotech sector offers a great avenue for retirement planning stocks. 
Via InvestorPlace
3 Gene Testing Stocks to Buy Before They Take Off
The future of gene testing is bright thanks to an aging population. Here are three companies leading the industry. 
Via InvestorPlace
Nephroblastoma Pipeline, NDA Approvals, Clinical Trials, and Emerging Drugs (2023) | Companies – Clarity Pharma, Y mAbs Therapeutics, Nova Biopharma, Eli Lilly, Illumina Radiopharma, Recombio and Other
Via AB Newswire
Illumina's Grail Acquisition Gains Support from GOP Lawmakers and Advocacy Groups Despite FTC Resistance
Republican lawmakers, state attorneys general, and several advocacy groups have expressed their support for Illumina Inc's (NASDAQ: ILMN) acquisition of Grail Inc, even as the Federal Trade Commission... 
Via Benzinga
Is CEO Resignation a Sign That Carl Icahn Can Save Illumina (ILMN) Stock?
The CEO of Illumina has stepped down due to pressure form Carl Icahn. ILMN stock has already started rising on the news. 
Via InvestorPlace
Expert Ratings for Illumina
Via Benzinga
$100 Invested In This Stock 10 Years Ago Would Be Worth $300 Today
Via Benzinga
Check Out What Whales Are Doing With ILMN
Via Benzinga
$100 Invested In This Stock 15 Years Ago Would Be Worth $500 Today
Via Benzinga
Broadcom Might Receive European Approval For $61B VMware Deal, UBS Closes Credit Suisse Takeover, Illumina CEO Steps Down Amid Activist Investor Carl Icahn's Pressure: Today's Top Stories
Reuters Broadcom Most Likely To Receive EU Approval For $61B VMware Merger 
Via Benzinga
Executive Shakeup at Illumina: CEO Francis deSouza Steps Down Amid Activist Investor Carl Icahn's Pressure
Illumina Inc (NASDAQ. 
Via Benzinga
Nasdaq, S&amp;P 500 Futures Signal Strong Start To Week On Hopes Of Fed Pause: Why This Analyst Is Pricing In A 20% Gain From Bear Market Low
Via Benzinga
Apple's Upcoming VR Headset Marks Significant New Product Debut In Almost 10 Years, Regulators Want Tighter Capital Requirements For Large US Banks, Software Configuration Error at Grail Causes Cancer Misdiagnosis: Today's Top Stories
Wall Street Journal 
Via Benzinga
Illumina Unusual Options Activity
Via Benzinga
Carl Icahn Buys The Dip Amidst Hindenburg's Short Report
Via Benzinga
Software Configuration Error at Grail Causes Cancer Misdiagnosis Scare; Could It Impact Illumina's Acquisition Plans?
Illumina Inc's (NASDAQ: ILMN) Grail Inc acquisition is reportedly in more hot water when Grail mistakenly sent form letters to 400 patients, suggesting they may have developed cancer. 
Via Benzinga
The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree
Big Pharma is facing a patent cliff that could siphon off billions in revenue. 
Via Investor's Business Daily
Elon Musk Praises Quality of Made in China Teslas, Exxon Eyes Double Output With New Fracking Tech, Netflix Shareholders Vote Against Fat Exec. Pay: Today's Top Stories
Benzinga 
Via Benzinga
Illumina Takes AI to Genomics: Launch of PrimateAI-3D for Accurate Disease Prediction
Illumina, Inc. (NASDAQ: ILMN) launched PrimateAI-3D, an artificial intelligence (AI) algorithm that predicts disease-causing genetic mutations in patients. 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Bill Ackman Thinks Rival Icahn's Firm Still Overvalued, Nvidia Nears $1 Trillion Market Cap, Freshpet's Largest Shareholder Pushes For Board Overhaul: Today's Top Stories
Benzinga 
Via Benzinga
Carl Icahn's Power Play at Illumina: Potential Board Changes and Management Overhaul
According to undisclosed sources, activist investor Carl Icahn is poised to secure enough shareholder support to place Andrew Teno, an Icahn nominee, to join the board of Illumina Inc (NASDAQ: ILMN). 
Via Benzinga
< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
31 32 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.